{
  "symbol": "BIIB",
  "year": 2023,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1809,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.275
  },
  "top_positive": [
    {
      "sent": "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
      "score": 0.9911
    },
    {
      "sent": "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
      "score": 0.9911
    },
    {
      "sent": "Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in AOCI, net of tax by component: June 30, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2022 $ ( 15.7 ) $ 15.1 $ ( 1.1 ) $ ( 163.2 ) $ ( 164.9 ) Other comprehensive income (loss) before reclassifications ( 0.2 ) ( 10.1 ) 0.7 18.7 9.1 Amounts reclassified from AOCI 1.4 ( 18.4 ) \u2014 \u2014 ( 17.0 ) Net current period other comprehensive income (loss) 1.2 ( 28.5 ) 0.7 18.7 ( 7.9 ) Balance, June 30, 2023 $ ( 14.5 ) $ ( 13.4 ) $ ( 0.4 ) $ ( 144.5 ) $ ( 172.8 ) June 30, 2022 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Gains (Losses) on Net Investment Hedges, Net of Tax (1) Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2021 $ ( 2.2 ) $ 53.8 $ 25.5 $ ( 44.8 ) $ ( 139.0 ) $ ( 106.7 ) Other comprehensive income (loss) before reclassifications ( 19.1 ) 129.5 12.6 2.7 ( 94.9 ) 30.8 Amounts reclassified from AOCI 1.1 ( 56.4 ) ( 38.1 ) \u2014 58.9 ( 34.5 ) Net current period other comprehensive income (loss) ( 18.0 ) 73.1 ( 25.5 ) 2.7 ( 36.0 ) ( 3.7 ) Balance, June 30, 2022 $ ( 20.2 ) $ 126.9 $ \u2014 $ ( 42.1 ) $ ( 175.0 ) $ ( 110.4 ) (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9 % equity interest in Samsung Bioepis in April 2022.",
      "score": 0.9849
    }
  ],
  "top_negative": [
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    },
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    },
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    }
  ],
  "forward_snippets": [
    "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "NCD National Coverage Decision NDA New Drug Application NDS New Drug Submission Neurimmune Neurimmune SubOne AG NMPA National Medicinal Products Administration OECD Organization for Economic Co-operation and\npatent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in millions, except per share a\nas implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in millions, except per share amounts) For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Revenue: Product, net $ 1,845.8 $ 2,054.9 $ 3,609.1 $ 4,121.2 Revenue from LEQEM\nticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards."
  ],
  "curated_text": "Symbol: BIIB. Year: 2023. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in AOCI, net of tax by component: June 30, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2022 $ ( 15.7 ) $ 15.1 $ ( 1.1 ) $ ( 163.2 ) $ ( 164.9 ) Other comprehensive income (loss) before reclassifications ( 0.2 ) ( 10.1 ) 0.7 18.7 9.1 Amounts reclassified from AOCI 1.4 ( 18.4 ) \u2014 \u2014 ( 17.0 ) Net current period other comprehensive income (loss) 1.2 ( 28.5 ) 0.7 18.7 ( 7.9 ) Balance, June 30, 2023 $ ( 14.5 ) $ ( 13.4 ) $ ( 0.4 ) $ ( 144.5 ) $ ( 172.8 ) June 30, 2022 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Gains (Losses) on Net Investment Hedges, Net of Tax (1) Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2021 $ ( 2.2 ) $ 53.8 $ 25.5 $ ( 44.8 ) $ ( 139.0 ) $ ( 106.7 ) Other comprehensive income (loss) before reclassifications ( 19.1 ) 129.5 12.6 2.7 ( 94.9 ) 30.8 Amounts reclassified from AOCI 1.1 ( 56.4 ) ( 38.1 ) \u2014 58.9 ( 34.5 ) Net current period other comprehensive income (loss) ( 18.0 ) 73.1 ( 25.5 ) 2.7 ( 36.0 ) ( 3.7 ) Balance, June 30, 2022 $ ( 20.2 ) $ 126.9 $ \u2014 $ ( 42.1 ) $ ( 175.0 ) $ ( 110.4 ) (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9 % equity interest in Samsung Bioepis in April 2022. Top negative sentences: If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Forward-looking snippets: Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. NCD National Coverage Decision NDA New Drug Application NDS New Drug Submission Neurimmune Neurimmune SubOne AG NMPA National Medicinal Products Administration OECD Organization for Economic Co-operation and\npatent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in millions, except per share a\nas implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in millions, except per share amounts) For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Revenue: Product, net $ 1,845.8 $ 2,054.9 $ 3,609.1 $ 4,121.2 Revenue from LEQEM\nticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; 3 Table of Contents \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards."
}